Normal View Dyslexic View

Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial

15 October 2025
Endocrine
BJSA
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Mallick U, Newbold K, Beasley M, Garcez K, Wadsley J, Johnson SJ et al.
Lancet 2025; 406: 52-62.
This study that included 504 patients with complete resection of low grade thyroid cancer did not benefit from additional radioiodine ablation. Five-year recurrence-free survival was similar: 96.3% ablation vs 97.9% in controls.
Comment: Conclusive trial showing radioiodine ablation is unnecessary in these patients.
Info
Copied!